RESUMEN
BackgroundDepressive disorders are prevalence among adolescents， with a higher incidence in females compared to males， often accompanied by more severe depressive symptoms. Sertraline is commonly prescribed for adolescent depressive disorder， however， its efficacy is only evident in certain patients. Currently， there is limited research on predicting the therapeutic efficacy of sertraline in female adolescents with depressive disorder. ObjectiveTo explore the relationship between personality traits， psychological resilience， coping style and the clinical efficacy of sertraline treatment in female adolescents with first-episode depressive disorder， in order to provide references for the treatment of this population. MethodsA total of 112 female adolescent patients with first-episode depressive disorder， meeting the diagnostic criteria of the International Classification of Diseases （tenth edition） （ICD-10）， and undergoing a 4-week treatment regimen with sertraline， were selected from the Second People's Hospital of Guizhou Province from February 2019 to January 2021.General demographic questionnaire， NEO Five-Factor Inventory （NEO-FFI）， Resilience Scale for Chinese Adolescents （RSCA）， Coping Style Scale for Middle School Students （CSSMSS）， Hamilton Anxiety Scale （HAMA） and Hamilton Depression Scale-17 item （HAMD-17） were used for assessment. Logistic regression analysis was used to investigate the factors influencing the clinical efficacy of sertraline in the treatment of female adolescents with first-episode depressive disorder. ResultsNeuroticism （β=-0.115， 95% CI： 0.807~0.984） could negatively predicted the therapeutic efficacy of sertraline in female adolescents with first-episode depressive disorder， whereas agreeableness （β=0.129， 95% CI： 1.025~1.264） and RSCA score （β=0.062， 95% CI： 1.004~1.128） could positively predict its therapeutic efficacy. ConclusionHigh neuroticism， low agreeableness and low psychological resilience may be the risk factors for the poor therapeutic effect of sertraline in the treatment of female adolescents with first-episode depressive disorder. ［Funded by 2019 Guiyang Science and Technology Program （number， Zhuke Contract ［2019］9-3-1）］